Ruxolitinib, a small molecule that directly targets Janus kinase 1/2 and slows the progression of liver fibrosis, has, however, demonstrated promising anti-fibrotic benefits in both in vitro and in vivo tests [22]. The gene discussed is JAK1; the disease is Hepatic fibrosis.